Exagen Inc. XGN
3.91 USD +0.15 (+3.86%)
As ofNov 18, 2026, 3:58 PM EST
3.57 Day range 3.96
2.59 52-week range 9.22
- YTD
- -35.77%
- 1 year
- -52.44%
News
seekingalpha.com Exagen: Q3 Raises Questions About The Turnaround (Rating Downgrade) Exagen is downgraded to Hold as Q3 results reveal slower revenue growth, weaker margins, and higher operating losses, clouding the turnaround outlook. XGN's Q3 revenue grew 7% year-over-year but…benzinga.com Canaccord Genuity Maintains Buy on Exagen, Lowers Price Target to $9 Canaccord Genuity analyst Kyle Mikson maintains Exagen (NASDAQ:XGN) with a Buy and lowers the price target from $11 to $9.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers PepGen (NASDAQ:PEPG) stock rose 126.6% to $5.42 during Tuesday's regular session. The company's market cap stands at $165.5 million. The company's, Q3 earnings came out today. Nano X Imaging
benzinga.com Exagen Q3 2026 Earnings Call Transcript Exagen (NASDAQ:XGN) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…benzinga.com Exagen Affirms FY2026 Sales Guidance of $72.000M-$75.000M vs $73.886M Est Exagen (NASDAQ:XGN) affirms FY2026 sales outlook from $72.000 million-$75.000 million to $72.000 million-$75.000 million vs $73.886 million estimate.
benzinga.com Exagen Q3 EPS $(0.25) Misses $(0.18) Estimate, Sales $18.417M Beat $18.343M Estimate Exagen (NASDAQ:XGN) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate of $(0.18) by 38.89 percent. This is a 31.58 percent decrease over losses of $(0.19) per…
benzinga.com Canaccord Genuity Maintains Buy on Exagen, Raises Price Target to $11 Canaccord Genuity analyst Kyle Mikson maintains Exagen (NASDAQ:XGN) with a Buy and raises the price target from $9 to $11.
